H-吴越投资2020-03-04 21:57
春节期间对血液灌流治疗进行初步研究,对采用全血灌流和血浆灌流的产品做了一些疏理,附以我个人的一些理解。相关公司列表如下:
表一、血浆吸附:
注:
(1)血浆吸附模式提前将血液中的血细胞分离出来,吸附效率更佳,还可以避免或减少血液相容性问题。血液相容性可能是因为离子树脂...查看全文
$Cytosorbents(CTSO)$ 美东时间 2019-08-06 盘后 披露财报,预期EPS -0.14 网页链接
$Cytosorbents(CTSO)$ 8-K - Current report Filed: 2019-07-26 AccNo: 0001144204-19-036249 Size: 30 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers 网页链接
$Cytosorbents(CTSO)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2019-07-09 AccNo: 0001144204-19-034168 Size: 461 KB 网页链接
$Cytosorbents(CTSO)$ 8-K - Current report Filed: 2019-07-09 AccNo: 0001144204-19-034169 Size: 283 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接
$Cytosorbents(CTSO)$ 8-K - Current report Filed: 2019-06-13 AccNo: 0001144204-19-030840 Size: 52 KBItem 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearItem 9.01: Financial Statements and Exhibits 网页链接
$Cytosorbents(CTSO)$ 内部交易: 2019-06-07,总裁 and CEO,Chan Phillip P. ,期权,20000普通股, $4.33
$Cytosorbents(CTSO)$ 内部交易: 2019-06-07,CFO,BLOCH KATHLEEN P. ,期权,10000普通股, $5.60
$Cytosorbents(CTSO)$ 8-K - Current report Filed: 2019-06-05 AccNo: 0001144204-19-029797 Size: 8 MBItem 5.07: Submission of Matters to a Vote of Security HoldersItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Cytosorbents(CTSO)$ 8-K - Current report Filed: 2019-06-04 AccNo: 0001144204-19-029770 Size: 19 KBItem 1.02: Termination of a Material Definitive Agreement 网页链接
$Cytosorbents(CTSO)$ 8-K - Current report Filed: 2019-05-08 AccNo: 0001144204-19-024330 Size: 122 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接